<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36745520</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-0960</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>The Australasian journal of dermatology</Title><ISOAbbreviation>Australas J Dermatol</ISOAbbreviation></Journal><ArticleTitle>Treatment-resistant systemic lupus erythematosus-associated hypocomplementic urticarial vasculitis successfully treated with belimumab.</ArticleTitle><Pagination><StartPage>301</StartPage><EndPage>303</EndPage><MedlinePgn>301-303</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ajd.13995</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pe&#xf1;uelas Leal</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-9627-780X</Identifier><AffiliationInfo><Affiliation>Consorcio Hospital General Universitario de Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labrandero Hoyos</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3270-7428</Identifier><AffiliationInfo><Affiliation>Consorcio Hospital General Universitario de Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Partarrieu Mej&#xed;as</LastName><ForeName>Felipe</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7602-9171</Identifier><AffiliationInfo><Affiliation>Consorcio Hospital General Universitario de Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grau Echevarr&#xed;a</LastName><ForeName>Andr&#xe9;s</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Consorcio Hospital General Universitario de Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorca Spr&#xf6;hnle</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4991-3145</Identifier><AffiliationInfo><Affiliation>Consorcio Hospital General Universitario de Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casanova Esquembre</LastName><ForeName>Andr&#xe9;s</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Consorcio Hospital General Universitario de Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esteve Mart&#xed;nez</LastName><ForeName>Altea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Consorcio Hospital General Universitario de Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaragoza Ninet</LastName><ForeName>Violeta</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Consorcio Hospital General Universitario de Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Australas J Dermatol</MedlineTA><NlmUniqueID>0135232</NlmUniqueID><ISSNLinking>0004-8380</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>73B0K5S26A</RegistryNumber><NameOfSubstance UI="C511911">belimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014581" MajorTopicYN="Y">Urticaria</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014657" MajorTopicYN="Y">Vasculitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">belimumab</Keyword><Keyword MajorTopicYN="N">hypocomplementemic urticarial vasculitis</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">urticarial vasculitis</Keyword><Keyword MajorTopicYN="N">vasculitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>12</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>6</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36745520</ArticleId><ArticleId IdType="doi">10.1111/ajd.13995</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Kolkhir P, Grakhova M, Bonnekoh H, Krause K, Maurer M. Treatment of urticarial vasculitis: a systematic review. J Allergy Clin Immunol. 2019;143(2):458-66. https://doi.org/10.1016/j.jaci.2018.09.007</Citation></Reference><Reference><Citation>Serarslan G, Okyay E. Clinical characteristics and treatment outcomes in patients with urticarial Vasculitis. North Clin Istanb. 2020;8(5):513-7. https://doi.org/10.14744/nci.2020.55476</Citation></Reference><Reference><Citation>European Medicines Agency. Benlysta summary of product characteristics; 2022 [cited 2022 Sep 1]. Available from: https://www.ema.europa.eu/en/documents/product-information/benlysta-epar-product-information_en.pdf</Citation></Reference><Reference><Citation>Ramos-Casals M, Ruiz-Irastorza G, Jim&#xe9;nez-Alonso J, Khamashta MA, Comit&#xe9; de Consenso sobre el uso de belimumab, Grupo de Trabajo de Enfermedades Autoinmunes Sist&#xe9;micas (GEAS) de la Sociedad Espa&#xf1;ola de Medicina Interna (SEMI). Recommendations on the use of belimumab in systemic lupus erythematosus. GEAS-SEMI Clinical Practice Guide. Rev Cl&#xed;n Esp. 2013;213(1):42-58. https://doi.org/10.1016/j.rce.2012.10.004</Citation></Reference><Reference><Citation>Valor-M&#xe9;ndez L, Schett G, Manger B. Treatment of refractory hypocomplementaemic urticarial vasculitis syndrome progressing to systemic lupus erythematosus with belimumab. Clin Exp Rheumatol. 2022;40(4):854-5. https://doi.org/10.55563/clinexprheumatol/m9dexe</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>